Incorporating Immunotherapy in the Management of Gastric Cancer Molecular and Clinical Implications.pdf (1.39 MB)
Incorporating immunotherapy in the management of gastric cancer: molecular and clinical implications
journal contribution
posted on 2023-06-10, 05:57 authored by Alessandro Agnarelli, Viviana Vella, Mark SamuelsMark Samuels, Panagiotis Papanastasopoulos, Georgios GiamasGeorgios GiamasGastric cancer has a median survival of 11 months, and this poor prognosis has not improved over the last 30 years. Recent pre-clinical data suggest that there is high tumour-related neoantigen expression in gastric cancer cells, suggesting that a clinical strategy that enhances the host’s immune system against cancer cells may be a successful approach to improve clinical outcomes. Additionally, there has been an increasing amount of translational evidence highlighting the relevance of PD-L1 expression in gastric cancer cells, indicating that PD-1/PD-L1 inhibitors may be useful. Several molecular subgroups of gastric cancer have been identified to respond with excellent outcomes to immunotherapy, including microsatellite instable tumours, tumours bearing a high tumour mutational burden, and tumours related to a chronic EBV infection. In gastric cancer, immunotherapy has produced durable responses in chemo-refractory patients; however, most recently there has been a lot of enthusiasm as several large-scale clinical trials highlight the improved survival noted from the incorporation of immunotherapy in the first line setting for advanced gastric cancer. Our review aims to discuss current pre-clinical and clinical data supporting the innovative role of immunotherapy in gastric cancer.
History
Publication status
- Published
File Version
- Published version
Journal
CancersISSN
2072-6694Publisher
MDPI AGExternal DOI
Issue
18Volume
14Page range
e4378 1-25Event location
SwitzerlandDepartment affiliated with
- Biochemistry Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2023-01-12First Open Access (FOA) Date
2023-01-12First Compliant Deposit (FCD) Date
2023-01-12Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC